31 results about "Renal cortex" patented technology

The invention is a simplified model on kidney rejection in animals and its setting approach. The method involves isolating dendritic cells from male mice and isolating T cells from female mice and then using the naive T cells in vitro to culture concurrently with male dendritic cells. Those activated T cells from female origin were injected into renal cortex in male mice for the purpose of attacking renal cortex. The animal model simulates the renal transplant rejection method to enable effective induction of renal transplant immune reaction.

The invention discloses a non-uniform graph search partitioning algorithm used for renal cortex positioning. The algorithm is characterized by comprising steps of (1), defining a multi-scale boundary function when segmentation starts so as to realize non-uniform sampling on nodes; (2), defining different weights according to characteristics of renal cortex during segmentation and using a max-flow / minimal-cut algorithm for detecting an optimal surface for segmentation. The segmentation speed is high and the segmentation accuracy is high according to the invention.

The invention belongs to the technical field of medicine and relates to 15-methylene-14-deoxy-11,12-dehydro-andrographolide derivatives. It has been proved by experiments that this type of compound significantly inhibits the migration and activation of hepatic stellate cells; significantly inhibits TGF‑β1-induced mesenchymal transition of human alveolar type II epithelial cells A549; significantly inhibits human renal cortical proximal tubule epithelial cells HK‑2 mesenchymal transition; significantly inhibits angiotensin Ⅱ (AngⅡ)-induced migration of primary human cardiac fibroblasts HCFB. Using this type of compound as an active ingredient to prepare anti-fibrosis drugs has high efficiency and low toxicity, and provides a new drug approach for the treatment and prevention of fibrosis-related diseases, thereby expanding the optional range of clinical drugs and having good application development prospect.

A drug carrier nanoparticle has been synthesized that can specifically target the proximal tubules of the kidneys. The nanoparticles accumulate in the kidneys to a greater extent than other organs (e.g., up to 3 or more times greater in the kidney than any other organ). They can encapsulate many classes of drug molecules. The nanoparticles are biodegradable and release the drug as they degrade. The particles can sustainably release a drug within the kidneys for up to two months. The nanoparticles are useful for the treatment of diseases that affect the proximal tubules, such as heart failure, liver cirrhosis, hypertension, and renal failure; the study of relative blood flow to the renal cortex and medulla; and delivery of agents to treat gout.

The invention discloses a three-dimensional perfusion type cell culture device and an application thereof. The three-dimensional perfusion type cell culture device comprises a box body, a cover body and an elastic clamp, wherein a first circular groove is formed in the top surface of the box body, and a second circular groove with the same radius as the first circular groove is formed in the bottom surface of the cover body. In the cell culture device disclosed by the invention, vessels consisting of polyester fibers are arranged on the bottom surface of the groove, and a cell or tissue explant is positioned between two layers of vessels to form 'sandwich' culture; the vessels consisting of polyester fibers are used for replacing a scaffold material, so that the dead angle volume in cell culture is minimized to better conform to the in-vivo physiological microenvironment. A culture solution inlet channel and a culture solution outlet channel are formed on the side wall of the box body of the culture device respectively, and a culture solution flows into the groove cavity through the solution inlet channel and flows out through the solution outlet channel so as to realize perfusion culture. By adopting the device disclosed by the invention, the embryonic stem cell / progenitor cell at the new renal cortex part is successfully differentiated into renal tubule tissues.

The invention discloses an application of a low-dose ursolic acid as a medicament for treating diabetic early nephropathy. The administration mode of the ursolic acid is oral administration, and the administration dose is 50-70mg / kg weight. The invention verifies that the oral administration of the low-dose ursolic acid has a remarkable inhibition action for the activation of ERK1 / 2 and JNK accesses in an MAPK access in a renal cortex induced by diabetes and the phosphorylation level of STAT3 tyrosine and can markedly lower the expression of iNOS in the renal cortex induced by the diabetes, and more importantly, the oral administration of the ursolic acid can inhabit the glomerular hypertrophy caused by the diabetes and the accumulation of type IV collagen at glomerulus, thereby indicating that the oral administration of the ursolic acid has a remarkable therapeutic effect on the diabetic early nephropathy.

The present invention relates to the new application of bendalysine in the field of pharmacy. Bendax lysine has the effect of significantly reducing blood sugar, glycosylated hemoglobin and urinary protein, can reduce the content of transforming growth factor TGF-β1 in renal cortex, and can reduce the content of non-enzymatic glycated protein (AGES) in renal cortex and serum AGES, It can significantly increase the total antioxidant capacity and the content of glutathione (GSH) in serum, have a certain effect on reducing laminin, and also have functions such as significantly reducing the activity of aldose reductase (AR). For the prevention and treatment of diabetic nephropathy.